The nuclear protein p68 (also known as Ddx5) is a prototypic member of the 'DEAD box' family of RNA helicases, which has been shown to be abnormally expressed and modified in colorectal tumors and to function as an important transcriptional regulator. Here, we show that p68 is modified in vivo on a single site (K53) by the small ubiquitin-like modifier-2 (SUMO-2). We demonstrate that the SUMO E3 ligase PIAS1 interacts with p68 and enhances its SUMO modification in vivo. To determine the functional consequences of SUMO modification, we compared the transcriptional activity of p68 and a K53R mutant that could not be SUMO-modified. Our data show that SUMO modification enhances p68 transcriptional repression activity and inhibits the ability of p68 to function as a coactivator of p53. These findings may be explained by the ability of wild type, but not K53R p68, to alter the modification state of chromatin by recruitment of histone deacetylase 1 (HDAC1).
Introduction
p68 is a prototypic member of the 'DEAD box' family of RNA helicases that have been shown to be involved in virtually all cellular processes requiring manipulation of RNA structure including transcription, pre-mRNA processing, RNA degradation, RNA export, ribosome assembly and translation (Ford et al., 1988; Linder et al., 1989; Tanner and Linder, 2001 ). p68 expression has been shown to be growth and developmentally regulated (Stevenson et al., 1998) , and changes in expression and modification have been implicated in tumor development (Causevic et al., 2001; Yang et al., 2007) .
p68 is an established ATPase and RNA helicase (Hirling et al., 1989; Iggo and Lane, 1989) and has been shown to be involved in pre-mRNA splicing (Liu, 2002; Guil et al., 2003) and, in the case of the yeast homolog, Dbp2 (Iggo et al., 1991) , to be important for both rRNA processing and nonsense-mediated mRNA decay (Bond et al., 2001) . These functions in RNA processing/decay are consistent with p68 functioning as an RNA helicase. However, there is now a growing body of evidence indicating that p68 also functions as a transcriptional regulator. The first indication that p68 plays a role in transcriptional regulation came from the finding that it acts as a coactivator for estrogen receptor alpha (ERa) (Endoh et al., 1999; Watanabe et al., 2001) . Subsequently, p68 was found to stimulate transcriptional activation mediated by CBP/p300 (Rossow and Janknecht, 2003) . We have previously demonstrated that p68 is a transcriptional coactivator of the tumor suppressor p53 and is important for the p53 DNA damage response (Bates et al., 2005) and that, in some contexts, it can act as a transcriptional repressor (Wilson et al., 2004) . Recently, p68 was shown to coactivate MyoD and to act as a coregulator of skeletal muscle differentiation (Caretti et al., 2007) . Moreover, our work and that of others showed that p68 is recruited to the promoters of the ERa-responsive pS2 gene in response to estrogen (Metivier et al., 2003) , the p53-target gene p21 following DNA damage (Bates et al., 2005) and chromatin regulatory regions of actively transcribed muscle genes (Caretti et al., 2007) , suggesting a role for p68 in transcriptional initiation. Taken together, these findings highlight an important role for p68 in transcriptional regulation.
We have previously shown that p68 is overexpressed and abnormally modified, predominantly by polyubiquitylation, in colorectal tumors (Causevic et al., 2001) . While pursuing that study, we observed other posttranslationally modified forms of p68 in a minority of tumors, which did not appear to be the result of ubiquitylation or phosphorylation. We were unable to identify conclusively the modification of these p68 species in the tumor samples. However, as analysis of the amino-acid sequence of p68 revealed several potential small ubiquitin-like modifier (SUMO) modification sites, we investigated whether p68 could be sumoylated in cell lines. SUMO modification has been shown to have a range of effects on its substrates, including alterations in subcellular localization/transport, interaction with other factors and, in the case of several transcription factors and regulators, changes in their ability to activate or repress transcription (reviewed in Gill, 2005 and Hay, 2005) . In this report, we show that, in cell lines, p68 is preferentially modified by SUMO-2 and to a lesser extent by the highly related SUMO-3, but is modified to a barely detectable level by SUMO-1, indicating a striking degree of specificity for the choice of p68 as a sumoylation substrate. This finding is supported by in vitro SUMO conjugation experiments, using recombinant proteins, which show a high degree of preference for p68 sumoylation by SUMO-2, as compared with SUMO-1. We have identified a single sumoylation site (K53) on p68 and show that PIAS1 acts as an E3 ligase for sumoylation of p68 by SUMO-2. We also show that sumoylation of p68 is important for its function as a transcriptional coactivator/repressor. Using our previously described assays demonstrating the ability of p68 to (a) stimulate p53 transcriptional activity (Bates et al., 2005) and (b) repress transcription from the constitutively active Herpes virus thymidine kinase (TK) promoter when targeted to this promoter via GAL4 (Wilson et al., 2004) , we show that a K53R mutant of p68, which cannot be sumoylated, is a better coactivator for p53 and is less able to repress transcription from the TK promoter. Finally, we show that, unlike wild-type (WT) p68, the K53R mutant is not able to interact with histone deacetylase 1 (HDAC1) providing a possible mechanism by which sumoylation may be modulating the ability of p68 to regulate transcriptional activity.
Results
p68 is modified by SUMO-2 and SUMO-3 but to a very low extent by SUMO-1 in vivo To determine whether p68 could be modified by SUMO in vivo, we co-transfected COS-7 cells with myc-tagged p68 and His-tagged SUMO-1, SUMO-2 or SUMO-3, respectively, and purified sumoylated proteins as described in the Materials and methods section. Using this approach, we found that p68 was efficiently modified by SUMO-2 and, to a lower extent by SUMO-3, but modified by SUMO-1 to a barely detectable level (Figure 1a ). To confirm that the differences in the efficiency of p68 sumoylation by SUMO-1, SUMO-2 and SUMO-3 were not owing to differences in expression of the three SUMO plasmids or their ability to modify other substrates, we first titered the plasmids to obtain equivalent levels of expression (data not shown) and examined whether p53, which previously had been shown to be modified by SUMO-1 (Gostissa et al., 1999; Rodriguez et al., 1999) , could be modified in this system. As shown in Figure 1b , p53 was modified to a similar extent by SUMO-2 and SUMO-3 and was also clearly modified, albeit to a lower extent, by SUMO-1. Moreover, all the SUMO proteins in the p68 and p53 sumoylation experiments were expressed at similar levels and capable of being conjugated to other proteins (Figure 1c and d) . We also checked that cotransfection of the SUMO plasmids did not affect expression of p68 or p53 (Figure 1e and f).
These findings thus indicate that, in cells, p68 is preferentially modified by SUMO-2, suggesting a measure of specificity in the ability of p68 to be modified by the different SUMO proteins. We also noted that, although for p53 the formation of multiple SUMO-2/-3 modified species (Tatham et al., 2001 ) was clearly visible, no obvious multiple SUMO-2/-3 species were observed for p68, even after very long exposures (data not shown).
We also carried out experiments to determine whether we could detect sumoylation of endogenous p68 protein in cell lines. As we did not observe sumoylated p68 in standard cell lysates, and because of the recognized difficulties in detecting sumoylated proteins, we used a HeLa cell line that stably expresses low levels of Histagged SUMO-2 (Vertegaal et al., 2004) and investigated whether we could detect sumoylated p68 after enrichment for sumoylated proteins by nickel pulldown. Using this system we detected a sumoylated p68 species in Western blots from HeLa SUMO-2 cells, but not in the control HeLa cells (Figure 1g ).
In vitro sumoylation of p68
To investigate further the specificity of modification by SUMO-2 as compared with SUMO-1, we performed two sets of in vitro sumoylation experiments. First, we examined sumoylation of in vitro translated 35 S-labeled p68 by purified recombinant SUMO-1 and SUMO-2 in the presence or absence of E1-activating enzyme SAE1/ SAE2 and the E2-conjugating enzyme Ubc9. We tested both full-length (FL) p68 (amino acids 1-614) and a truncated version including amino acids 1-501 (see below). As shown in Figure 2a , p68 was modified by both SUMO-1 and SUMO-2 in this system and, as expected, omission of SUMO, SAE1/SAE2 or Ubc9 abrogated modification. The use of glutathione S-transferase (GST)-tagged SUMO-1 as an additional control confirmed the ability of SUMO-1 to modify p68. Moreover, the appearance of additional, higher molecular weight modified forms of p68 with SUMO-2 suggested that, in this system, SUMO-2 chains were being formed. These, coupled with the finding that SUMO-1 could also modify p68, suggest either that other, normally cryptic, sumoylation sites on p68 are modified by SUMO-1 in vitro and/or that the specificity observed in cells is not reproduced in vitro implying that perhaps other factors in the cell may impart specificity to the p68 sumoylation process.
We then investigated in vitro sumoylation of purified recombinant p68 using recombinant Ubc9, SAE1/SAE2, SUMO-1 and SUMO-2. For these experiments, we used a truncated version of p68 (amino acids 1-501) as it was expressed and purified much more efficiently than the FL protein, and both proteins behaved similarly in the experiments using in vitro-translated p68. Moreover, as discussed below, p68 is modified on a single site, K53, in vivo. These in vitro SUMO conjugation experiments were performed using previously optimized fixed amounts of recombinant p68, SAE1/SAE2, SUMO-1 and SUMO-2 and increasing amounts of Ubc9, as described in the Materials and methods section. As Figure 1 p68 is modified by SUMO-2, to a lesser extent by SUMO-3, but to a barely detectable level by SUMO-1 in cells. (a-f) Western blots of proteins from COS-7 cells co-transfected with plasmids encoding His-tagged SUMO-1/SUMO-2/SUMO-3 and myctagged p68 (a, c and e) or p53 (b, d and f). Sumoylated proteins were Western-blotted with (a) 9E10 to detect myc-tagged p68; (b) DO-1 to detect p53; and (c and d) a His-specific antibody to detect all His-tagged/sumoylated proteins or SUMO. Expression of p68 and p53 was monitored by blotting total cell lysates with 9E10 (e) and DO-1 (f) antibodies, respectively; actin levels were monitored as loading controls. (g) Western blots of nickel pulldowns from HeLa and HeLa 6His SUMO-2 (HeLa SUMO-2) cells probed with (i) p68-specific (2907) and (ii) His-specific antibodies. p68, p53: unmodified p68/p53, binding nonspecifically to the nickel beads (note the high level of unmodified p68 seen to bind nonspecifically to the nickel beads in G is due to the long exposure required to detect endogenous sumoylated p68); p68*, p53*: sumoylated p68/p53; NS: nonspecific cross-reaction with His antibody; SUMO*: sumoylated proteins.
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A-MF Jacobs et al shown in Figure 2b , in this system p68 was considerably more efficiently modified by SUMO-2 than by SUMO-1, a finding that is consistent with our previous observations of p68 sumoylation in cell lines, but is different from the results obtained with in vitro-translated p68. However, the presence of multiple other components in the wheatgerm extract makes interpretation of the data obtained with in vitro-translated p68 difficult. The results with the purified recombinant p68, SUMO, SAE1/SAE2 and Ubc9 suggest that at least some of the specificity seen for sumoylation of p68 by SUMO-2 may be intrinsic to these protein components.
p68 is sumoylated on a single site (K53) in cells Because, in cells, p68 is preferentially modified by SUMO-2, we decided to pursue our studies of p68 sumoylation by SUMO-2. Analysis of the amino-acid sequence of p68 revealed several potential sumoylation sites. However, a deletion derivative lacking the Nterminal 60 amino acids was not sumoylated in cells (data not shown). We therefore made lysine to arginine changes at position 53, which lies within a potential sumoylation site (PKFEK) and the adjacent lysine (K56), and tested whether these p68 mutants could be modified by SUMO-2 in co-transfection experiments as before. As shown in Figure 3a , mutation of K53 abrogates sumoylation of p68, suggesting that there is a single sumoylation site (K53) on p68. (A K56R mutation had no effect on p68 sumoylation.) As an additional control, we generated a glutamic acid to alanine mutation in the p68 SUMO consensus site (E55A) (Sampson et al., 2001) and showed that this mutation also abrogates sumoylation ( Figure 3a ). Western blotting of lysates from cells that had been transfected with the WT and K53R, K56R or E55A p68 mutants in a parallel experiment showed that all proteins were expressed at similar levels ( Figure 3b ). In all cases the p68 proteins were myc-tagged, as before, to distinguish them from endogenous p68.
PIAS1 acts as an E3 ligase for SUMO-2 conjugation to p68 PIAS proteins have been shown to increase the efficiency of SUMO conjugation by acting as E3 ligases (reviewed in Hay, 2005 ), therefore, we tested whether PIAS1 or PIASy could increase the efficiency of SUMO-2 S-labeled) p68 (full length (FL) and truncated derivative incorporating amino acids 1-501) is modified by SUMO-1, GST-tagged SUMO-1 ( þ *) and SUMO-2. Sumoylation is dependent on the presence of the E1-activating enzyme, SAE1/ SAE2 (SAE1/2), and the E2 conjugating enzyme, Ubc9. The minor modification seen in the absence of SAE1/2 is due to trace amounts of SAE1/2 in the wheat germ extract used for in vitro translation of p68. (b) Western blot showing modification of recombinant p68 by SUMO-1 and SUMO-2 in the presence of SAE1/SAE2 and increasing amounts of Ubc9 (0.6-6 mM). p68 was detected with an antibody (MAD-1) directed against the DEAD motif. FL, full length; 1-501, encoding amino acids 1-501. p68*, sumoylated p68. Figure 3 p68 is modified on a single site (K53) in cells. Western blots showing (a) sumoylated p68 proteins from COS-7 cells cotransfected with p68 (WT, K53R, K56R or E55A) and SUMO-2 and (b) relative expression of WT, K53R, K56R and E55A p68 in total protein lysates from COS-7 cells. Transfected (myc-tagged) p68 proteins were detected using 9E10 and actin levels were used to ensure equal loading in (b). p68*, sumoylated p68.
p68 sumoylation modulates its transcriptional activity A-MF Jacobs et al conjugation to p68. This was performed by co-transfecting COS-7 cells with myc-tagged p68, His-tagged SUMO-2 and HA-tagged PIAS1 or PIASy and purifying His-tagged (sumoylated) proteins as before. Figure 4a shows that PIAS1 significantly increases the level of p68 sumoylation, whereas PIASy causes a decrease of p68 sumoylation, perhaps through competing for SUMO-2. These findings suggest that PIAS1 acts as the E3 ligase for SUMO-2 conjugation to p68. As we had not observed significant modification of p68 by SUMO-1, we wondered whether SUMO-1 modification of p68 could be stimulated by co-transfection of PIAS1. However, as shown in Figure 4b , even with the addition of PIAS1, SUMO-1 modification of p68 was not detectable, indicating that PIAS1 does not stimulate SUMO-1 modification of p68. In this system, PIAS1 and PIASy were expressed at similar levels ( Figure 3c ) and were both active as demonstrated by their ability to autosumoylate (Figure 3d ) (Kotaja et al., 2002) ; in fact, PIASy was considerably more active, giving multiple sumoylated forms.
p68 and PIAS1 interact in vitro and in vivo Following our observation that PIAS1 stimulates the conjugation of SUMO-2 to p68, we examined whether p68 can interact with PIAS1. (We had previously shown that p68 interacts with PIAS1, but not with PIASy in a yeast two-hybrid assay (data not shown)). We first determined whether p68 and PIAS1 interact in vitro by performing GST pulldowns. As shown in Figure 5a , GST-tagged p68 interacts with PIAS1 but not with PIASy, whereas the GST-tagged vector control interacts with neither. We then investigated whether PIAS1 and p68 also interact in cultured cells. HEK293 cells were transfected with a plasmid encoding myc-tagged PIAS1 to determine whether the expressed PIAS1 could coimmunoprecipitate with endogenous p68 from nuclear extracts. All nuclear extracts were treated with DNase/ RNase before the immunoprecipitation (IP) to exclude the possibility that any observed interaction was merely via nucleic acid. As shown in Figure 5b , p68 and PIAS1 co-immunoprecipitate from nuclear extracts indicating that they interact in the cell and provide further evidence and PIASy proteins (HA-tagged) were detected using an HAspecific antibody while p68 (myc-tagged) was detected using 9E10. p68*, PIAS1/y*: sumoylated, p68 or PIAS1/y. p68 sumoylation modulates its transcriptional activity A-MF Jacobs et al suggesting that PIAS1 is indeed the E3 ligase for sumoylation of p68. These findings are consistent with our results showing that PIAS1, but not PIASy, enhances sumoylation of p68.
Sumoylation of p68 is important for its transcriptional repression activity and its interaction with HDAC1 Sumoylation is often associated with transcriptional repression (reviewed in Gill, 2005; Hay, 2005) . By targeting GAL4-tagged p68 to promoters containing GAL4-binding sites, we had previously shown that p68
can repress transcription from the Herpes virus TK promoter (Wilson et al., 2004) . Therefore, we investigated whether sumoylation of p68 has any effect on this activity. For this experiment, U2OS cells were cotransfected with a TK promoter/luciferase reporter plasmid containing two copies of the GAL4 binding site together with GAL4-tagged WT, K53R or E55A p68 and transcription was measured using standard luciferase activity assays. (The use of the E55A ruled out the possibility that effects are owing to other modifications of K53.) Firstly, the relative expression levels of WT, K53R and E55A p68 were checked to ensure that all plasmids were expressed at equivalent levels ( Figure 6a ). As shown in Figure 6b , the ability of the K53R or E55A p68 to repress transcription was significantly reduced as compared with WT p68; this was particularly pronounced when low amounts of DNA were transfected, where the repression activity of the mutants was less than 50% that of the WT. These results indicate that sumoylation of p68 is important for its transcriptional repression activity. The enhancement of transcriptional repression activity by sumoylation has been suggested to be mediated by HDAC recruitment for both the CRD1 domain of p300 and the R domain of Elk1 (Girdwood et al., 2003; Yang and Sharrocks, 2004) . We had previously shown that p68 co-immunoprecipitates and co-elutes, from gel filtration columns, with HDAC1 (Wilson et al., 2004) . We therefore examined whether sumoylation of p68 had any effect on its ability to interact with HDAC1. HEK293 cells were transfected with plasmids encoding either WT or K53R myc-tagged p68, or the myc-tagged vector control, and the ability of WT and the sumoylation-deficient K53R p68 to co-immunoprecipitate with endogenous HDAC1 from nuclear extracts was determined by IP/Western blotting. As before, reciprocal IP/ Westerns were carried out to confirm the interaction, with appropriate controls. Figure 7 shows the Western blot results for both p68 (myc) IP (Figure 7a ) and the HDAC1 IP ( Figure 7b) ; these demonstrate that, although WT p68 co-immunoprecipitates efficiently with HDAC1, the K53R p68 does not. For both IPs it was clear that both the transfected, myc-tagged, WT p68 and the K53R mutant (Figure 7a ) as well as HDAC1 (Figure 7b ) could be immunoprecipitated efficiently, ruling out the possibility that the lack of co-immunoprecipitation between the K53R p68 and HDAC1 was merely the result of the 9E10 antibody being unable to immunoprecipitate myc-tagged K53R p68. Our data thus suggest that SUMO modification of p68 is important for its interaction with HDAC1 and provide a possible mechanism for the impaired transcriptional repression activity of the K53R p68.
K53R p68 is a better p53 coactivator
As p68 sumoylation appears to be important for its transcriptional repression activity, and we had previously shown that p68 is a potent stimulator of p53 transcriptional activity (Bates et al., 2005) , it was important to determine whether sumoylation also S-labeled) PIAS1 and PIASy and GST-tagged p68, showing both input and PIAS1 interacting with p68. A GST-vector control is included. Note the band showing PIAS1 interacting with p68 runs lower in the gel since it is displaced by the GST-tagged p68, which has a similar electrophoretic mobility (data not shown). (b) Co-immunoprecipitation (co-IP) of myctagged PIAS1 and endogenous p68 from HEK293 nuclear extracts (NE). Reciprocal IPs were carried out to confirm the interaction: i.e., p68 IP/myc (PIAS1) Western and myc (PIAS1) IP and p68 Western. Myc-tagged PIAS1 and p68 were detected in Western blots using 9E10 and the p68-specific antibody 2907, respectively. Cells transfected with vector alone (Cont.) and IPs with an irrelevant antibody (Cont. IP) acted as controls. NE denotes total nuclear extract; in each case 7% of the amount used in the IP.
p68 sumoylation modulates its transcriptional activity A-MF Jacobs et al affected the ability of p68 to coactivate p53. Our previous p53 coactivation experiments had made use of the synthetic p53-dependent promoter PG13 linked to the luciferase reporter (Bates et al., 2005) . Therefore, we used this system to examine the effect of p68 sumoylation on its ability to stimulate p53 transcriptional activity. H1299 (p53-null) cells were co-transfected with plasmids expressing WT or K53R p68, p53 and PG13-Luc, and p53 transcriptional activity was determined by measuring luciferase activity. In each case, the expression of both p53 and p68 were first checked by Western blotting to ensure that WT and K53R p68 were expressed at equivalent levels and that they did not have any effect on p53 protein levels (Figure 8a) . In parallel experiments, standard luciferase assays were performed; these showed that, at p68 concentrations at which p53 coactivation was more than threefold, K53R p68 was approximately 1.5-fold more active in terms of its ability to stimulate p53 activity (Figure 8b ). (Similar results were obtained with the E55A mutant -data not shown.) These findings suggest that sumoylation of p68 inhibits its ability to act as a transcriptional coactivator and are consistent with our findings that sumoylation is important for the interaction of p68 with HDAC1 and for transcriptional repression by p68 (see above).
Discussion
In this report, we have demonstrated that the DEAD box protein p68 is preferentially modified by SUMO-2 in vivo (Figure 1a ). Our findings indicate that there is a remarkable degree of specificity in the choice of p68 as a sumoylation substrate, whereas the lack of modification by SUMO-1 can be attributed to differences between SUMO-1 and SUMO-2 (approximately 50% identity), the low level of modification seen by SUMO-3 is more surprising because SUMO-2 and SUMO-3 are 96% identical in the processed forms and are considered to be A range of p68 plasmid amounts (25-100 ng) was transfected for a better comparison; both endogenous and transfected (GAL4-tagged) p68 were detected using PAb204. (b) Relative transcriptional repression activity of WT, K53R and E55A GAL4-tagged p68 (ranging from 1-7.5 ng of transfected plasmid DNA) as determined by measuring luciferase activity of pTK-Luc. The luciferase activity in the presence of the GAL4 vector control (pcG4) was taken as 100% (i.e., no repression) and the activity in the presence of p68 (WT, K53R or E55A) was calculated relative to this. The relative repression activity was obtained by subtracting the relative activity from 100 to give the p68 repression activity relative to that of the pCG4 vector, which would be 0. Note the amounts of p68 used for the Western blot are higher than in the luciferase assays to allow detection in the blot. The amounts of DNA used in the luciferase assays were calculated empirically to give values in the linear range. In all experiments, 300 ng of pTK-Luc and 50 ng of pcG4 were used and the total DNA transfected was made up to a total of 500 ng with pcDNA3 as recommended by the Fugene manufacturer (Roche Diagnostics Ltd.).
Figure 7
Interaction of WT and K53R p68 with HDAC1. Co-IP of myc-tagged WT and K53R p68 with endogenous HDAC1 from HEK293 nuclear extracts. (a) myc-tagged p68 (WT or K53R) was immunoprecipitated with 9E10 and immunoprecipitated p68 and HDAC1 were detected by Western blotting with myc-and HDAC1-specific antibodies, respectively. (b) Reciprocal co-IP of p68 and HDAC1. In this case, HDAC1 was immunoprecipitated and p68 (WT and K53R) and HDAC1 were detected by Western blotting. Cells transfected with a vector alone (Cont.) and IPs with an irrelevant antibody (Cont. IP) acted as controls. NE denotes total nuclear extract; in each case 7% of the amount used in the IP. HC, heavy chain.
p68 sumoylation modulates its transcriptional activity A-MF Jacobs et al functionally equivalent (Saitoh and Hinchey, 2000; Tatham et al., 2001) . Interestingly, the p66 subunit of DNA polymerase d was recently reported to be modified by SUMO-3 and not SUMO-2 in vivo (Liu and Warbrick, 2006) . Moreover, we have not observed multiple SUMO-2/SUMO-3 species (Figure 1a ) that possibly represent polymeric SUMO chains for p68; this is somewhat surprising because SUMO-2/SUMO-3 generally form polymeric chains on their substrates (Tatham et al., 2001) . We identified K53 as a single site for sumoylation on p68 (Figure 3a ), indicating that, in cells, p68 is sumoylated on a single site, K53, by the addition of one SUMO-2 moiety. We have also shown that PIAS1 interacts with p68 and enhances its sumoylation by SUMO-2 (Figure 4a) . Additionally, and consistent with the previously observed specificity for modification by SUMO-2, PIAS1 did not stimulate SUMO-1 modification of p68 (Figure 4b) . Sumoylation has been shown to alter localization and/or function of proteins, and is known to modulate transcriptional activity of a variety of proteins involved in transcriptional regulation (reviewed in Seeler and Dejean, 2003; Gill, 2005; Hay, 2005) . We found no obvious difference in nuclear localization of K53R p68 compared with the WT (data not shown). Therefore, as we had previously shown that p68 can act both as a transcriptional repressor (Wilson et al., 2004 ) and a coactivator of p53 (Bates et al., 2005) , we examined the effect of sumoylation on these functions of p68. The K53R mutant appeared to be a better p53 coactivator (Figure 8b ), suggesting that sumoylation inhibits the ability of p68 to stimulate p53-dependent transcription. Our data also showed that sumoylation is important for transcriptional repression by p68 (Figure 7b ) and are supported by our finding that K53R p68 did not coimmunoprecipitate with HDAC1 ( Figure 6 ). Although these results do not unequivocally demonstrate an HDAC-dependence for transcriptional repression by p68, they are consistent with previous reports suggesting that sumoylation promotes transcriptional repression through the recruitment of HDACs (Girdwood et al., 2003; Yang and Sharrocks, 2004) . In this respect it is interesting to note that, although the K53R p68 does not co-immunoprecipitate with HDAC1, the WT p68 coimmunoprecipitating with HDAC1 does not appear to be SUMO modified, as seen by its electrophoretic mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) ( Figure 7 ) and we have not been able to immunoprecipitate sumoylated forms of endogenous p68 (data not shown). This suggests either that SUMO is being removed from p68, by SUMO-specific proteases, during the preparation of the samples after co-immunoprecipitation or, more likely, that, although p68 sumoylation may be important for its interaction with HDAC/recruitment into a repression complex, it is not required for its retention within such a complex. Such a hypothesis has been proposed to explain the observation that although only a small proportion of a given transcription factor is SUMOmodified at any given time, sumoylation often has profound effects on transcriptional repression (Hay, 2005) . The DEAD box protein DP103, which has been shown to repress transcription of the early growth response 2 (Egr2) transcription factor, at least in part through HDAC recruitment (Gillian and Svaren, 2004) , has also been found to repress steroidogenic factor 1 (SF-1) activity through promoting its sumoylation and relocalization (Lee et al., 2005) , providing another example of sumoylation being involved in regulating the transcriptional activity of a DEAD box protein.
Taken together, these data are strongly indicative of SUMO modification of p68 modulating its function as a transcriptional regulator and favoring its action as a repressor of transcriptional activity, perhaps through recruitment of corepressors. In this way, SUMO modification of p68 could act as a form of switch for the selective interaction with coactivator or corepressor partners, thus modulating p68 activity from a transcriptional coactivator to a repressor/corepressor. and HEK293 cells were used because our previous work had shown that they were ideal for expression of sumoylated proteins and purification of nuclear extracts, respectively (Causevic et al., 2001; Wilson et al., 2004) . H1299 (p53-null) and U2OS cells were used for the p68 transcriptional activity assays as described previously (Wilson et al., 2004; Bates et al., 2005) . HeLa and Hela 6His SUMO-2 (stably expressing Histagged SUMO-2) were used to examine sumoylation of endogenous p68 protein. All cells were maintained in 5% CO 2 at 371C in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (all supplied by Invitrogen, Paisley, UK).
Materials and methods

Cell lines
Plasmids
Plasmids expressing WT and K53R/E55A mutant p68 included untagged versions in pcDNA3 (Invitrogen), as well as myc epitope-tagged versions in pSG5 (Stratagene, La Jolla, CA, USA), GAL4-tagged versions (in a pcDNA3 derivative expressing amino acids 1-147 of GAL4 (Wilson et al., 2004) ) and GST-tagged versions in pEBG2T (Ogilvie et al., 2003) . Plasmids expressing His-tagged SUMO-1, SUMO-2 and SUMO-3 were generated in pcDNA3; the plasmid expressing myc-tagged PIAS1 was in pSG5; plasmids expressing HAtagged PIAS1 and PIASy were in pKW2T (a gift from Mienrad Busslinger, Vienna Biocentre, Austria); Luciferase reporter plasmids included the p53-responsive PG13-Luc (el-Deiry et al., 1993) and pTK-Luc bearing two copies of the GAL4-binding site (a gift from Brian Wilson, McGill University, Montreal, Canada).
Antibodies
The following antibodies were used: p68: PAb204 (mouse monoclonal; Upstate, Dundee, UK), MAD-1 (mouse monoclonal raised against the DEAD motif) and 2907 (rabbit polyclonal raised against the C-terminal 15 amino acids of p68); p53: DO1 (mouse monoclonal; Santa Cruz Biotechnology, Santa Cruz, CA, USA); myc epitope: 9E10 (mouse monoclonal; Sigma-Aldrich, Poole, UK); HA-epitope: 12CA5 (mouse monoclonal; Roche Diagnostics Ltd, Burgess Hill, UK); HDAC1: PC544 (rabbit polyclonal; BD Biosciences, Oxford, UK); His tag: 27471001 (mouse monoclonal; Amersham/ Pharmacia, GE Healthcare, Chalfont St Giles, UK); actin: A2066 (rabbit polyclonal; Sigma). Appropriate anti-mouse and anti-rabbit secondary antibodies were purchased from DAKO (Ely, UK)
Expression and purification/detection of His 6 -tagged SUMOconjugated proteins COS-7 cells were seeded at 3 Â 10 5 per 10 cm plate and transfected 16 h later using lipofectamine (Invitrogen) with plasmids encoding myc-tagged p68, His-tagged SUMO-1, SUMO-2 and SUMO-3 and HA-tagged PIAS1/PIASy as described in the Results section. About 1.5 mg of DNA was transfected for all DNAs except for SUMO-2 for which 0.25 mg was used. Forty hours after transfection His-tagged (sumoylated) proteins were isolated under denaturing conditions on nickel (Ni-NTA) agarose beads as described previously (Rodriguez et al., 1999) and, after separation of proteins by SDS-PAGE, myc-tagged/sumoylated p68 was detected by Western blotting using standard conditions. Expression and purification of recombinant proteins p68 (amino acids 1-501) was cloned in pHISTEV as an Nterminal His-tagged protein, expressed in Escherichia coli BL21 (DE3) Rosetta cells and purified using Nickel affinity chromatography as described previously (Mendoza et al., 2003) . SUMO-1, GST-tagged SUMO-1, SUMO-2, Ubc9 and SAE1/SAE2 were expressed in E. coli B834 and purified as described previously (Desterro et al., 1997; Tatham et al., 2001) .
In vitro SUMO conjugation assays SUMO conjugation assays were performed using two different protocols:
(a) 35 S-methionine-labeled p68 was generated using 1 mg of p68 plasmid DNA and a wheatgerm coupled transcription/translation system (Promega, Southampton, UK) and SUMO modification of the radioactively labeled p68 was performed in a 10 ml reaction mix containing an adenosine triphosphate (ATP) regeneration system (50 mM Tris (pH 7.6), 5 mM MgCl 2 , 2 mM ATP, 10 mM creatine phosphate, 3.5 U/ml creatine kinase and 0.6 U/ml inorganic pyrophosphatase), 0.1 mM SAE1/SAE2, 4.4 mM Ubc9, 9 mM SUMO-1 or SUMO-2, protease inhibitors EDTA-free (Roche) and 5 mM dithiothreitol (DTT). The reaction was incubated for 4 h at 371C and terminated by adding SDS-PAGE sample buffer containing 5 mM b-mercaptoethanol. Proteins were separated by SDS-PAGE and radioactively labeled proteins were visualized on a phosphorimager (Fuji BAS 1500, MacBAS software, Fuji Film, Tokyo, Japan). (b) Sumoylation of recombinant p68 protein was performed in a 10 ml reaction mix containing 50 mM Tris (pH 7.5), 5 mM MgCl 2 , 2 mM ATP, 5 mM DTT, 0.1 mM SAE1/SAE2, 0.6-6 mM Ubc9, 0.9 mM SUMO-1 or SUMO-2 and 0.4425 mM p68. The reaction was incubated for 4 h at 371C and terminated by adding SDS-PAGE sample buffer containing 5 mM b-mercaptoethanol. Proteins were separated by SDS-PAGE, subjected to Western blotting and probed with MAD-1, a monoclonal antibody against the DEAD motif in p68.
GST pulldowns GST-tagged p68 and vector control were expressed in 293 cells as described previously (Ogilvie et al., 2003) and purified on glutathione beads using standard conditions. PIAS1 and PIASy were translated in vitro using the TNT kit from Promega and GST pulldowns were performed as described previously (Hsieh et al., 1999) .
Expression of WT and K53R mutants of p68, nuclear extract preparation and co-immunoprecipitation HEK293 cells were seeded at 3 Â 10 6 per 15 cm plate and transfected 16 h later by the calcium phosphate method (Webster and Perkins, 1999) with plasmids encoding myctagged WT and K53R p68 (20 mg DNA per plate). Forty-eight hours after transfection nuclear extract preparation and coimmunoprecipitation experiments were performed as described previously (Bates et al., 2005) , except that the IP wash buffers contained different concentrations of Igepal (Sigma) for different IP antibodies as follows: myc 0.5% and HDAC1 1%.
Transcriptional coactivation/repression assays H1299 and U2OS cells were seeded in a 24-well dish at 2.5 Â 10 4 cells per well and were transfected 16 h later with plasmids encoding (a) untagged WT or K53R/E55A p68, p53 and the PG13/luciferase reporter for measuring p53 coactivation (H1299), or (b) GAL4-tagged WT or K53R/E55A p68 and pTK-Luc promoter/reporter for measuring transcriptional repression (U2OS). Transfections were performed using p68 sumoylation modulates its transcriptional activity A-MF Jacobs et al Fugene (Roche Diagnostics Ltd) and luciferase activity was measured 24 h later using the E1501 kit from Promega. Luciferase activity was calculated as an average from three independent experiments that were, in each case, performed in triplicate. Relative luciferase activity was obtained by comparison with activity obtained with the transfected promoter/ reporter construct alone, which was set to 1 for measuring coactivation and to 100% for measuring repression.
